Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.

Published

Journal Article

We used a replication-incompetent, single-cycle, alphavirus replicon vector system to produce virus-like replicon particles (VRP) expressing the extracellular domain of human cytomegalovirus (CMV) glycoprotein B or a pp65/IE1 fusion protein. Efficient production methods were scaled to produce pilot lots and clinical lots of each alphavirus replicon vaccine component. The vaccine induced high-titered antibody responses in mice and rabbits, as measured by ELISA and CMV neutralization assays, and robust T-cell responses in mice, as measured by IFN-gamma ELISPOT assay. A toxicity study in rabbits showed no adverse effects in any toxicology parameter. These studies support clinical testing of this novel CMV alphavirus replicon vaccine in humans.

Full Text

Duke Authors

Cited Authors

  • Reap, EA; Morris, J; Dryga, SA; Maughan, M; Talarico, T; Esch, RE; Negri, S; Burnett, B; Graham, A; Olmsted, RA; Chulay, JD

Published Date

  • October 16, 2007

Published In

Volume / Issue

  • 25 / 42

Start / End Page

  • 7441 - 7449

PubMed ID

  • 17870214

Pubmed Central ID

  • 17870214

International Standard Serial Number (ISSN)

  • 0264-410X

Digital Object Identifier (DOI)

  • 10.1016/j.vaccine.2007.08.016

Language

  • eng

Conference Location

  • Netherlands